Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

Metastatic Soft-tissue Sarcoma Clinical Trial

Official title:
A Randomized Phase II Trial of Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

Status Active, not recruiting

Clinical Trial Summary

The hypothesis of this study is that the response rate of soft tissue sarcoma will be improved with the addition of PD-1 and CTLA-4 inhibition to cabozantinib, and that cabozantinib priming will increase the response to nivolumab and ipilimumab.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04551430
Study type	Interventional
Source	Washington University School of Medicine
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	January 5, 2021
Completion date	June 1, 2030

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04874311` - Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma	Phase 2
Recruiting	`NCT04757337` - Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma Patients	Phase 3
Withdrawn	`NCT04877587` - Gemcitabine With Ascorbate Including Adolescents	Early Phase 1
Recruiting	`NCT05099666` - Lurbinectedin + Doxorubicin In Leiomyosarcoma	Phase 1/Phase 2
Completed	`NCT03022448` - Geriatric Assessmen of Elderly "Unsuited" Patients Receiving Trabectedin in First Line Treatment For Advanced Soft Tissue Sarcomas (STS)
Terminated	`NCT05100628` - A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma	Phase 1
Recruiting	`NCT05180695` - HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas	Phase 1/Phase 2